RxDoctor Payments Data

Emily Scott, MD

Cardiovascular Disease · San Diego, CANPI 1003910456

Payments from drug & device makers

$2,678in general payments, 2019–2025

Across 137 payments — averaging $19.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$949
  • Pfizer$285
  • Amgen$240
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$178
  • Johnson & Johnson$119
  • Boehringer Ingelheim$118
  • plus $789 from 17 others

What the payments were for

  • Food & beverage$2,678100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,678 in reported general payments places this provider in the 50th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California

Medicare billing

Part B allowed, 2024
$60,422
Medicare patients
122
Services billed
526

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban64$63,478
EntrestoSacubitril/Valsartan47$43,479
Repatha SureclickEvolocumab32$41,305
EliquisApixaban28$38,933
JardianceEmpagliflozin38$26,710
Praluent PenAlirocumab16$7,553
Valsartan86$1,645
Atorvastatin Calcium59$836
Rosuvastatin Calcium49$823
Metoprolol Succinate26$447
Nitroglycerin14$438
Losartan Potassium33$363
ClopidogrelClopidogrel Bisulfate23$359
Carvedilol43$299
Isosorbide Mononitrate ErIsosorbide Mononitrate19$290

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$119$63,47864 claims
NovartisEntresto$949$43,47947 claims
PfizerEliquis$285$38,93328 claims
Boehringer IngelheimJardiance$118$26,71038 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 2,184 cardiovascular disease providers in California.

Other cardiovascular disease in San Diego

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →